



# Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



## Brief report

## Rapid antibiotic susceptibility testing (RAST) of blood cultures in enterobacteria with inducible chromosomal AmpC-type $\beta$ -lactamase



Blanca Carrasco, Gloria Zaragoza, David M. Arana, Yolanda Hernández-Hermida, Juan-Ignacio Alós\*

Servicio de Microbiología, Hospital Universitario de Getafe, Getafe, Madrid, Spain

### ARTICLE INFO

#### Article history:

Received 4 September 2023

Accepted 7 December 2023

Available online 18 January 2024

#### Keywords:

Enterobacteria

Inducible chromosomal AmpC

Rapid antibiotic susceptibility testing

Blood cultures

Disk diffusion method

### ABSTRACT

**Introduction:** Early and adequate treatment of bloodstream infections decreases patient morbidity and mortality. The objective is to develop a preliminary method for rapid antibiotic susceptibility testing (RAST) in enterobacteria with inducible chromosomal AmpC.

**Methods:** RAST was performed directly on spiked blood cultures of 49 enterobacteria with inducible chromosomal AmpC. Results were read at 4, 6 and 8 h of incubation. Commercial broth microdilution was considered the reference method. Disks of 10 antibiotics were evaluated.

**Results:** The proportion of readable tests at 4 h was 85%. All RAST could be read at 6 and 8 h.

For most antibiotics, the S or R result at 4, 6 and 8 h was greater than 80% after tentative breakpoints were established and Area of Technical Uncertainty was defined.

**Conclusions:** This preliminary method seems to be of practical use, although it should be extended to adjust the breakpoints and differentiate them by species.

© 2023 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

## Pruebas rápidas de sensibilidad antibiótica de hemocultivos con enterobacterias portadoras de $\beta$ -lactamasa tipo AmpC cromosómica inducible

### RESUMEN

#### Palabras clave:

Enterobacterias

AmpC cromosómica inducible

Pruebas rápidas de sensibilidad antibiótica

Hemocultivos

Método de difusión en disco

**Introducción:** El tratamiento precoz y adecuado de las bacteriemias disminuye la morbilidad y mortalidad de los pacientes. El objetivo es desarrollar un método preliminar de pruebas rápidas de sensibilidad antibiótica (PRSA) en enterobacterias con AmpC cromosómica inducible.

**Métodos:** Las PRSA se realizaron directamente de hemocultivos simulados positivos para 49 enterobacterias con AmpC cromosómica inducible. Los resultados se leyeron a las 4, 6 y 8 horas de incubación. La microdilución en caldo comercial se consideró el método de referencia. Se evaluaron discos de 10 antibióticos.

**Resultados:** La proporción de pruebas legibles a las 4 horas fue del 85%. Todas las PRSA pudieron leerse a las 6 y 8 horas.

Para la mayoría de los antibióticos, el resultado S o R a las 4, 6 y 8 horas fue superior al 80%, después de que se establecieran puntos de corte provisionales y se definiera el área de incertidumbre técnica.

**Conclusiones:** Este método preliminar parece ser de utilidad práctica, aunque debería ampliarse para ajustar los puntos de corte y diferenciar por especies.

© 2023 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

### Introduction

Adequate early management of sepsis is imperative to decrease mortality and morbidity. Administration of correct antimicrobial

\* Corresponding author.

E-mail address: [nachoalos@telefonica.net](mailto:nachoalos@telefonica.net) (J.-I. Alós).

**Table 1**

Breakpoints and ATU established at each incubation time interval and percentage of strains included in each category.

Antibiotic	Zone diameter breakpoint (mm)								
	4 h			6 h			8 h		
	S <sub>≥</sub>	R<	ATU	S <sub>≥</sub>	R<	ATU	S <sub>≥</sub>	R<	ATU
Cefotaxime	15 (55.6%)	13 (44.4%)	13–14 (0%)	17 (57.1%)	15 (40.8%)	15–16 (2.1%)	18 (57.1%)	16 (36.7%)	16–17 (6.2%)
Ceftazidime	14 (55.6%)	13 (44.4%)	13 (0%)	15 (59.2%)	15 (40.8%)	–	16 (59.2%)	15 (40.8%)	15 (0%)
Cefepime	19 (60%)	14 (30%)	14–18 (10%)	22 (54.5%)	14 (27.3%)	14–21 (18.2%)	24 (54.5%)	14 (27.3%)	14–23 (18.2%)
Piperacilin/tazobactam	12 (51.4%)	12 (48.6%)	–	14 (46.9%)	12 (38.8%)	12–13 (14.3%)	15 (42.9%)	12 (36.7%)	12–14 (20.4%)
Meropenem	17 (63.6%)	11 (4.6%)	11–16 (31.8%)	18 (65.3%)	10 (4.1%)	10–17 (30.6%)	18 (73.5%)	9 (4.1%)	9–17 (22.4%)
Imipenem	16 (72.7%)	12 (2.3%)	15–12 (25%)	16 (75.5%)	14 (8.2%)	14–15 (16.3%)	16 (79.6%)	14 (8.2%)	14–15 (12.2%)
Amikacin	15 (63.6%)	12 (2.3%)	12–14 (34.1%)	15 (75.5%)	12 (2.1%)	12–14 (22.4%)	15 (79.6%)	12 (2.1%)	12–14 (18.3%)
Tobramycin	13 (64.4%)	12 (20%)	12 (15.6%)	14 (55.1%)	12 (16.3%)	12–13 (28.6%)	14 (63.2%)	12 (18.4%)	12–13 (18.4%)
Gentamicin	12 (88.6%)	7 (11.4%)	7–11 (0%)	12 (89.8%)	7 (10.2%)	7–11 (0%)	13 (89.8%)	7 (10.2%)	7–12 (0%)
Ciprofloxacin	19 (58.1%)	16 (25.6%)	16–18 (16.3%)	20 (65.3%)	15 (14.3%)	15–19 (20.4%)	20 (69.4%)	16 (12.2%)	16–19 (18.4%)

ATU: Area of Technical Uncertainty; S: susceptible, standard dosing regimen; R: resistant.

therapy within the first hours of symptom onset increases the survival rate.<sup>1</sup>

Reliable and early information on antibiotic susceptibility allows early adjustment of treatment. The tests performed in laboratories for the determination of antibiotic susceptibility allow us to obtain results in 16–20 h. Therefore, it is necessary to implement rapid antibiotic susceptibility testing (RAST), mainly in severe infections, which will allow us to shorten the time of the results.<sup>2</sup>

In 2019 the European Committee on Antimicrobial Susceptibility Testing (EUCAST) publishes a method of RAST performed directly from positive blood culture bottles. It is a simple method that allows results to be obtained between 4 and 8 h. At present it has been validated for some bacterial species<sup>3</sup> but no studies have been performed to develop RAST in enterobacteria with inducible chromosomal AmpC, prevalent in severe infections. Our objective is to develop a preliminary method for RAST in enterobacteria with inducible chromosomal AmpC.

## Material and methods

To simulate real conditions, BACTEC™ Plus Aerobic/F blood culture bottles (Becton, Dickinson and Company, Sparks MD, USA), were inoculated with 5 ml of human blood and 1 ml of a solution with 100–200 CFU/ml, which was previously prepared by diluting a 0.5 McFarland suspension of each bacterial isolate 1/1,000,000.<sup>4</sup> They were incubated in the automated BACTEC FX system (Becton, Dickinson and Company), being positive for 7–15 h.

The disk diffusion method was performed as described by the RAST EUCAST method.<sup>3</sup> Blood culture broth was inoculated on a Müller-Hinton plate (Oxoid, Basingstoke, UK), disks of the different antibiotics (piperacilin/tazobactam, cefotaxime, ceftazidime, cefepime, imipenem, meropenem, ciprofloxacin, gentamicin, tobramycin and amikacin) were placed and the plate was subsequently incubated at 35 ± 2 °C. Reading was performed at 4, 6 and 8 h.

Simultaneously, a subculture was performed on blood agar, incubating the plate for 16–20 h to subsequently confirm identification by MALDI-TOF mass spectrometry (MICROFLEX LT/SH (Bruker Daltonics)) and determine antibiotic susceptibility by microdilution in broth, considered the reference method, using the MicroScan® WalkAway® automated system.

RAST were performed directly from spiked blood cultures of 12 *Enterobacter cloacae*, 12 *Citrobacter freundii*, 13 *Klebsiella aerogenes* and 12 *Serratia marcescens*. All strains came from blood cultures of patients preserved in our collection. Strains with different antibiotic susceptibility were chosen to establish the tentative breakpoints: inducible phenotype: 27 strains; derepressed phenotype: 10 strains; quinolone resistance: 16 strains; aminoglycoside

resistance: 9 strains; ESBL production: 3 strains; carbapenem resistance: 9 strains.

The percentage of readable tests at 4, 6 and 8 h was calculated.

Tentative breakpoints were established for the inhibition zones at 4, 6 and 8 h. For this purpose, we considered as a breakpoint of resistance in each time interval the inhibition zone with the largest diameter of the strains that were resistant with the reference method and as a breakpoint of susceptibility of each antibiotic the inhibition zone with the smallest diameter of the strains considered susceptible with the reference method. In some antibiotics the overlap between S and R isolates was problematic, we introduced Area of Technical Uncertainty (ATU), considering as such the diameter zones between both breakpoints.

## Results

The proportion of readable tests at 4 h of incubation was 85%. All RAST could be read at 6 and 8 h.

When tentative breakpoints and ATU were established, as described in section “Material and methods”, the results shown in Table 1 were obtained. For most antibiotics, an S or R result at 4, 6 and 8 h greater than 80% was obtained. The percentage of strains included in the ATU category ranged from 0% for gentamicin and ceftazidime at all time intervals to 34% for amikacin at 4 h.

Categorical agreement at different incubation time intervals is shown in Table 2.

## Discussion

It is important to shorten the period until effective therapy is administered in patients with severe illness; earlier results of antibiotic sensitivity testing may contribute to this.

RAST is a valuable and simple method to accelerate antimicrobial susceptibility testing and provide optimal antibiotic treatment for patients.

By modifying the breakpoints of the inhibition zone diameters at 4–8 h as described in section “Material and methods” and defining the ATU category, we eliminate errors, leaving a percentage of susceptible and resistant strains that depends on each antibiotic and the reading time. Since for most antibiotics an S or R result at 4, 6 and 8 h greater than 80% is obtained, it is, in our opinion, of practical use.

Our method developed on enterobacteria with inducible chromosomal AmpC directly from positive BC flasks provides results in one standard working day. It is uncomplicated to perform and requires only equipment and skills already available in clinical laboratories.

With the tentative breakpoints and ATU that were defined in this study, there are no errors.

**Table 2**

Results of antibiotic–bacteria categorical agreement at different incubation time intervals.

Antibiotic	Categorical agreement (CA)		
	4 h reading CA	6 h reading CA	8 h reading CA
Cefotaxime	36/36 (100%)	49/49 (100%)	47/49 (95.9%)
Ceftazidime	36/36 (100%)	49/49 (100%)	49/49 (100%)
Cefepime	41/44 (93.2%)	45/49 (91.8%)	45/49 (91.8%)
Piperacilin/tazobactam	37/37 (100%)	45/49 (91.8%)	42/49 (85.7%)
Meropenem	33/44 (75%)	38/49 (77.5%)	42/49 (85.7%)
Imipenem	33/44 (75%)	41/49 (83.7%)	43/49 (87.7%)
Amikacin	29/44 (65.9%)	38/49 (77.5%)	40/49 (81.6%)
Tobramycin	38/45 (84.4%)	35/49 (71.4%)	40/49 (81.6%)
Gentamicin	44/44 (100%)	49/49 (100%)	49/49 (100%)
Ciprofloxacin	37/43 (86.01%)	40/49 (81.6%)	41/49 (83.7%)

CA: categorical agreement.

But there are limitations: not all results were available within 4 h, a relatively low number of strains have been used and no differentiation between species has been made.

Therefore, we consider the breakpoints defined to be preliminary. The study would have to be extended in the future to adjust the breakpoints. In addition, it would be desirable to differentiate them by species and to decrease the ATU intervals, thus increasing the values interpreted as S or R.

### Funding

No funding has been received for this work.

### Conflict of interest

The authors have no conflict of interest.

### References

1. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. *Lancet*. 2018;392:75–87, [http://dx.doi.org/10.1016/S0140-6736\(18\)30696-2](http://dx.doi.org/10.1016/S0140-6736(18)30696-2).
2. Jasuja JK, Zimmermann S, Burckhardt I. Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for positive blood cultures in clinical practice using a total lab automation. *Eur J Clin Microbiol Infect Dis*. 2020;39:1305–13, <http://dx.doi.org/10.1007/s10096-020-03846-3>.
3. EUCAST rapid antimicrobial susceptibility testing (RAST) directly from positive blood culture bottles. Version 1.1; May 2019. <https://eucast.org/> [accessed 15.09.22].
4. Åkerlund A, Jonasson E, Matuschek E, Serrander L, Sundqvist M, Kahlmeter G, et al. EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories. *J Antimicrob Chemother*. 2020;75:3230–8, <http://dx.doi.org/10.1093/jac/dkaa333>.